Mar 28, 2018 03:21 PM IST
We are now ready to enter the European market with our Insulin Glargine as a biosimilar, in the second half of this year, said Kiran Mazumdar Shaw, CMD, Biocon.
- Jan 19, 2018 12:28 PM IST
The company is trying to combine forces with companies who have been successful in biosimilars, said Kiran Mazumdar Shaw, CMD, Biocon.
- Mar 27, 2017 09:21 AM IST
The European Medicines Agency (EMA) said that the suspension has been ordered for all drugs for which the bioequivalence studies were conducted by Micro Therapeutic Research Labs at two sites in India.
- Feb 10, 2017 04:28 PM IST
Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.
- Jan 12, 2017 08:21 AM IST
Bengaluru-based biopharmaceutical firm Biocon on Wednesday said US drug regulator has accepted its partners Mylan‘s biologics license application (BLA) for the proposed biosimilar of breast cancer drug Trastuzumab through the 351(k) pathway.
- Nov 04, 2015 12:23 PM IST
Nexium (used to treat certain stomach and esophagus problem) & Pulmicort (used to prevent asthma attacks) supply may boost company's export formulation business during the quarter. Hence, export formulation business may grow around 35-40 percent year-on-year.
- Oct 28, 2015 06:04 PM IST
The warning, issued to Novartis's generic drugs unit Sandoz on Oct. 22, came after FDA officials inspected its Turbhe and Kalwa sites in western India in August 2014.
- Jul 30, 2015 01:10 PM IST
Kotak has a buy rating on Cipla with a target price of Rs 730 per share. Expecting launch of other two strengths (USD 600 million) in days to follow , the brokerage says Cipla will receive mark-up and profit share.
- Dec 23, 2014 08:21 PM IST
The multi-layered deal involves UK-based GlaxoSmithKline (GSK) acquiring the Swiss major's vaccine business, while the latter would purchase GSK's cancer drugs portfolio.
- Nov 07, 2014 10:04 AM IST
Brokerages are worried about the stocks and stress that approval of Sun Pharma-Ranbaxy deal will be key driver. They feel that this negative surprise may benefit Dr Reddy's.
- Sep 01, 2014 11:38 AM IST
According to Surajit Pal, both Natco Pharma and Dr. Reddy‘s share exclusivity and two-three more companies are also expected to join the same.
- Jun 27, 2012 04:45 PM IST
CNBC-TV18's Archana Shukla reports that German pharma MNC Sandoz has filed a citizen's petition against Ranbaxy asking it to forfeit its first-to-file (FTF) status for the blockbuster drug Nexium.
- Jun 25, 2012 05:14 PM IST
Natco Pharma Ltd has lost a patent litigation against Israel's Teva Pharmaceutical Industries Ltd in the US over multiple sclerosis treatment drug, Copaxone.